These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

799 related articles for article (PubMed ID: 17996590)

  • 21. [Monoclonal gammopathies of undetermined significance called "MGUS"].
    Clément F
    Schweiz Med Wochenschr; 1989 Jul; 119(27-28):970-8. PubMed ID: 2508215
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
    Kyle RA
    Eur J Haematol Suppl; 1989; 51():70-5. PubMed ID: 2516809
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic factors in monoclonal gammopathy of undetermined significance.
    Sackmann F; Pavlovsky MA; Corrado C; Pizzolato M; Alejandre M; Pavlovsky S
    Haematologica; 2008 Jan; 93(1):153-4. PubMed ID: 18166806
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Monoclonal gammopathy of undetermined significance: why identification of these patients and assessment of their skeletons is important.
    Berenson JR; Yellin O
    Clin Lymphoma Myeloma; 2009 Aug; 9(4):311-5. PubMed ID: 19717382
    [TBL] [Abstract][Full Text] [Related]  

  • 25. UK Myeloma Forum (UKMF) and Nordic Myeloma Study Group (NMSG): guidelines for the investigation of newly detected M-proteins and the management of monoclonal gammopathy of undetermined significance (MGUS).
    Bird J; Behrens J; Westin J; Turesson I; Drayson M; Beetham R; D'Sa S; Soutar R; Waage A; Gulbrandsen N; Gregersen H; Low E;
    Br J Haematol; 2009 Oct; 147(1):22-42. PubMed ID: 19673884
    [No Abstract]   [Full Text] [Related]  

  • 26. Risk of progression in smouldering myeloma and monoclonal gammopathies of unknown significance: comparative analysis of the evolution of monoclonal component and multiparameter flow cytometry of bone marrow plasma cells.
    Pérez-Persona E; Mateo G; García-Sanz R; Mateos MV; de Las Heras N; de Coca AG; Hernández JM; Galende J; Martín-Nuñez G; Bárez A; Alonso JM; Martín A; López-Berges C; Orfao A; San Miguel JF; Vidriales MB
    Br J Haematol; 2010 Jan; 148(1):110-4. PubMed ID: 19821821
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Monoclonal gammopathies of undetermined significance].
    Krizalkovicová V; Maisnar V; Pour L; Radocha J; Hájek R
    Klin Onkol; 2008; 21(4):160-4. PubMed ID: 19102222
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Retrospective analysis of progression to multiple myeloma or related disorders in 114 patients with monoclonal gammopathy of undetermined significance in a single institute].
    Yokota S; Urasaki Y; Nakamura Y; Bessho M
    Rinsho Ketsueki; 2012 Mar; 53(3):303-9. PubMed ID: 22499046
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Monoclonal gammopathy of undetermined significance does not affect outcomes in patients undergoing solid organ transplants.
    Jimenez-Zepeda VH; Heilman RL; Engel RA; Carey EJ; Freeman C; Rakela J; Mulligan DC; Fonseca R; Stewart AK
    Transplantation; 2011 Sep; 92(5):570-4. PubMed ID: 21712755
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic Impact of Serum Heavy/Light Chain Pairs in Patients With Monoclonal Gammopathy of Undetermined Significance and Smoldering Myeloma: Long-Term Results From a Single Institution.
    Magnano L; Fernández de Larrea C; Elena M; Cibeira MT; Tovar N; Aróstegui JI; Pedrosa F; Rosiñol L; Filella X; Yagüe J; Bladé J
    Clin Lymphoma Myeloma Leuk; 2016 Jun; 16(6):e71-7. PubMed ID: 27013181
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pathogenesis and progression of monoclonal gammopathy of undetermined significance.
    Bladé J; Rosiñol L; Cibeira MT; de Larrea CF
    Leukemia; 2008 Sep; 22(9):1651-7. PubMed ID: 18668131
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Diagnosis, risk stratification and management of monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
    van de Donk NW; Mutis T; Poddighe PJ; Lokhorst HM; Zweegman S
    Int J Lab Hematol; 2016 May; 38 Suppl 1():110-22. PubMed ID: 27161311
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Arterial and venous thrombosis in patients with monoclonal gammopathy of undetermined significance: incidence and risk factors in a cohort of 1491 patients.
    Za T; De Stefano V; Rossi E; Petrucci MT; Andriani A; Annino L; Cimino G; Caravita T; Pisani F; Ciminello A; Torelli F; Villivà N; Bongarzoni V; Rago A; Betti S; Levi A; Felici S; Gentilini F; Calabrese E; Leone G;
    Br J Haematol; 2013 Mar; 160(5):673-9. PubMed ID: 23240810
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Survival of cancer patients with prior monoclonal gammopathy of undetermined significance.
    Gregersen H; Sørensen HT; Engebjerg MC; Jensen P; Severinsen MT; Nørgaard M
    Eur J Intern Med; 2010 Dec; 21(6):564-8. PubMed ID: 21111946
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Multiple myeloma: clinical features and indications for therapy.
    Dispenzieri A; Kyle RA
    Best Pract Res Clin Haematol; 2005; 18(4):553-68. PubMed ID: 16026737
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Epidemiology of Monoclonal Gammopathy of Undetermined Significance (MGUS): The experience from the specialized registry of hematologic malignancies of Basse-Normandie (France).
    Cabrera Q; Macro M; Hebert B; Cornet E; Collignon A; Troussard X
    Cancer Epidemiol; 2014 Aug; 38(4):354-6. PubMed ID: 24880205
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
    Kyle RA; Rajkumar SV
    Curr Hematol Malig Rep; 2010 Apr; 5(2):62-9. PubMed ID: 20425398
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Role of Diagnosis and Clinical Follow-up of Monoclonal Gammopathy of Undetermined Significance on Survival in Multiple Myeloma.
    Sigurdardottir EE; Turesson I; Lund SH; Lindqvist EK; Mailankody S; Korde N; Björkholm M; Landgren O; Kristinsson SY
    JAMA Oncol; 2015 May; 1(2):168-74. PubMed ID: 26181017
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, and curcumin: a randomized, double-blind placebo-controlled cross-over 4g study and an open-label 8g extension study.
    Golombick T; Diamond TH; Manoharan A; Ramakrishna R
    Am J Hematol; 2012 May; 87(5):455-60. PubMed ID: 22473809
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New tools for detecting occult monoclonal gammopathy, a cause of secondary osteoporosis.
    Faiman B; Licata AA
    Cleve Clin J Med; 2010 Apr; 77(4):273-8. PubMed ID: 20360121
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 40.